Peptides in Endocrinology

Overview

Endocrinology — the study of hormones and the glands that produce them — is fundamentally a peptide science. The hypothalamic-pituitary system, which coordinates most of the body's endocrine function, operates through a cascade of peptide hormones: hypothalamic releasing and inhibiting peptides regulate anterior pituitary peptide hormones, which in turn control peripheral endocrine glands. Peptide-based therapeutics and diagnostics occupy a central position in endocrine medicine, from growth hormone replacement to GnRH analogs for reproductive disorders.

The Hypothalamic-Pituitary Peptide Axes

Growth Hormone Axis

The growth hormone axis is regulated by two opposing hypothalamic peptides:

• Growth hormone-releasing hormone (GHRH) — a 44-amino-acid peptide that stimulates GH synthesis and secretion from pituitary somatotrophs. Therapeutic analogs include sermorelin (GHRH(1-29)), tesamorelin (a stabilized GHRH analog approved for HIV-associated lipodystrophy), and CJC-1295 (a modified GHRH analog with extended half-life).
• Somatostatin — a 14 or 28-amino-acid inhibitory peptide that suppresses GH (and many other hormone) secretions. Therapeutic analogs (octreotide, lanreotide, pasireotide) are used for acromegaly, neuroendocrine tumors, and Cushing's disease.

Growth hormone itself is a 191-amino-acid single-chain polypeptide (technically a protein rather than a peptide by size) that mediates its anabolic and metabolic effects both directly and through hepatic production of insulin-like growth factor-1 (IGF-1).

The ghrelin signaling pathway provides a third regulatory input, with growth hormone secretagogue peptides (GHRP-6, GHRP-2, hexarelin, ipamorelin) acting through the GHS-R1a receptor to stimulate GH release independently of GHRH.

Diagnostic applications include the GHRH stimulation test and the macimorelin test (an oral GH secretagogue used to diagnose adult GH deficiency).

Hypothalamic-Pituitary-Gonadal (HPG) Axis

The HPG axis is governed by GnRH (gonadotropin-releasing hormone), a decapeptide secreted in pulsatile fashion by hypothalamic neurons. Pulsatile GnRH stimulates pituitary LH and FSH release, which drive gonadal steroidogenesis and gametogenesis.

Therapeutic GnRH-related peptides include:

• Gonadorelin — bioidentical GnRH used diagnostically to assess pituitary gonadotroph function and therapeutically to restore LH pulsatility
• GnRH agonists (leuprolide, triptorelin, nafarelin) — continuous administration paradoxically suppresses the HPG axis through receptor desensitization and downregulation. Used for prostate cancer, endometriosis, precocious puberty, and assisted reproduction.
• GnRH antagonists (degarelix) — directly block the GnRH receptor, producing immediate gonadal suppression without the initial stimulatory "flare" of agonists. Used for advanced prostate cancer.
• Kisspeptin — an upstream peptide that stimulates GnRH neurons. Kisspeptin analogs are under investigation as a physiological means of triggering LH surges for ovulation induction and as a diagnostic tool for reproductive disorders.

Hypothalamic-Pituitary-Adrenal (HPA) Axis

The HPA axis stress response is initiated by corticotropin-releasing hormone (CRH), a 41-amino-acid hypothalamic peptide that stimulates ACTH release from pituitary corticotrophs. ACTH, a 39-amino-acid peptide derived from proopiomelanocortin (POMC), stimulates cortisol production from the adrenal cortex.

Diagnostic applications of HPA axis peptides include:

• CRH stimulation test — differentiating pituitary from ectopic ACTH production in Cushing's syndrome
• Cosyntropin (synthetic ACTH(1-24)) stimulation test — assessing adrenal cortical reserve
• Dexamethasone suppression testing — evaluating HPA axis feedback integrity

Hypothalamic-Pituitary-Thyroid Axis

TRH (thyrotropin-releasing hormone) is a tripeptide (pyroGlu-His-Pro-NH2) that stimulates thyroid-stimulating hormone (TSH) release from pituitary thyrotrophs. While TRH stimulation testing was historically important for diagnosing subtle thyroid axis disorders, the availability of sensitive TSH assays has reduced its routine clinical use. TRH also stimulates prolactin release, a property used in neuroendocrine research.

Posterior Pituitary Peptides

Unlike the anterior pituitary (which produces its own peptide hormones in response to hypothalamic signals), the posterior pituitary stores and releases peptides synthesized in hypothalamic nuclei:

• Vasopressin (ADH) — a nonapeptide produced in the supraoptic and paraventricular nuclei, regulating water reabsorption in the collecting duct and arterial vasoconstriction. Desmopressin, a synthetic vasopressin analog with enhanced antidiuretic selectivity, is used for diabetes insipidus, nocturnal enuresis, and hemophilia A.
• Oxytocin — a nonapeptide produced in the paraventricular and supraoptic nuclei, involved in uterine contraction, milk ejection, social bonding, and trust. Synthetic oxytocin is used clinically for labor induction and postpartum hemorrhage prevention.

Metabolic Endocrine Peptides

Insulin and Related Peptides

Insulin — a 51-amino-acid disulfide-linked hormone produced by pancreatic beta cells — is the most widely used therapeutic peptide in medicine. Modern insulin therapy includes rapid-acting, short-acting, intermediate-acting, and long-acting analogs, all produced through recombinant technology.

Related metabolic peptides include:

• Pramlintide — a synthetic analog of amylin, co-secreted with insulin from beta cells, that slows gastric emptying, suppresses postprandial glucagon, and promotes satiety
• C-peptide — the connecting peptide cleaved during proinsulin processing, used as a biomarker of endogenous insulin production

GLP-1-Based Therapeutics

The incretin axis has become the most active area of peptide endocrinology, with GLP-1 receptor agonists and dual/triple agonists (tirzepatide, retatrutide, survodutide) representing a major expansion of peptide therapeutics for type 2 diabetes, obesity, and potentially cardiovascular and hepatic disease. See GLP-1 Research for detailed coverage.

Bone and Calcium Metabolism

Peptide hormones are central to calcium homeostasis and bone metabolism:

• Parathyroid hormone (PTH) — an 84-amino-acid peptide from the parathyroid glands that raises blood calcium through bone resorption, renal calcium reabsorption, and vitamin D activation. Teriparatide (PTH(1-34)) is approved for osteoporosis as an anabolic bone agent.
• Abaloparatide — a synthetic analog of PTH-related protein (PTHrP) that selectively activates the RG conformation of the PTH1 receptor, promoting bone formation with less bone resorption than teriparatide.
• Calcitonin — a 32-amino-acid peptide from thyroid C-cells that inhibits osteoclast activity and lowers blood calcium. Salmon calcitonin (more potent than human calcitonin) has been used for osteoporosis and Paget's disease.

Emerging Research Directions

Active areas of endocrine peptide research include:

• Multi-receptor agonists — single molecules that activate multiple hormone receptors simultaneously for synergistic metabolic benefits
• Oral peptide delivery — technologies enabling oral administration of peptides traditionally limited to injection (oral semaglutide as a pioneering example)
• Peptide-based diagnostics — using peptide hormone measurements (stimulated and basal) for precision diagnosis of endocrine disorders
• Chronobiology — optimizing peptide dosing based on circadian patterns of endogenous hormone secretion

Related Topics

• Growth Hormone Axis — the GH-IGF-1 regulatory system
• HPG Axis — reproductive endocrine regulation
• HPA Axis — stress response endocrine pathway
• GLP-1 Receptor Signaling — incretin axis mechanisms
• Insulin — the foundational therapeutic peptide in endocrinology